TradingForProfitPro

JOHNSON & JOHNSON VACCINE D1

Long
NYSE:JNJ   Johnson & Johnson
Johnson & Johnson was the first American company to develop a vaccine against the corona virus. More than 20 companies took part in the race for a panacea. But only Johnson was able to achieve significant results. The company conducted tests on animals (monkeys). They started to develop antibodies. The government gave the company $ 456 million to test people and speed up the manufacturing process. This disease has spread all over the world and more than 20,000,000 people need this drug. This vyktsin can become a product of the year and create a huge stir among the violence of the entire planet. The United States is in particular need for the drug. The country with the highest incidence rate. The country's government has already signed a $ 1 billion deal with the company. And most likely this is not the last contract for the company. Such profit of the company cannot but stimulate the stock to rise. Therefore, for Johnson and Johnson, this vaccine can become a gold source of income.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.